Isocitrate dehydrogenase (IDH) is inhibited by a combination of the cell’s own energy signals, environmental toxins, excess substrate, and, in the case of mutant forms found in cancer, targeted pharmaceutical drugs. The specific inhibitors depend on which of the three isoforms you’re looking at: IDH1 and IDH2 use NADP+ as a cofactor and work in the cytoplasm and mitochondria respectively, while IDH3 uses NAD+ and operates exclusively in the mitochondria as part of the citric acid cycle.
ATP and NADH: The Cell’s Built-In Brakes
IDH3, the version that drives the citric acid cycle, is tightly controlled by the cell’s energy status. When a cell already has plenty of energy, it slows down the cycle to avoid wasting resources. The two main signals that trigger this slowdown are ATP and NADH.
ATP is the cell’s energy currency. When ATP levels are high relative to ADP, it signals that the cell doesn’t need to produce more energy, and IDH3 activity drops. NADH works similarly: it’s the product of the reaction IDH3 catalyzes (converting NAD+ to NADH in the process of oxidizing isocitrate). When NADH accumulates faster than the cell can use it, the high NADH-to-NAD+ ratio acts as product inhibition, slowing the enzyme down. This is classic feedback regulation, where the outputs of a pathway restrain the pathway itself.
On the flip side, ADP and calcium ions activate IDH3. Calcium is particularly potent: at concentrations around 1.2 micromolar, it can produce an 8-fold increase in IDH3 activity by making the enzyme much more responsive to its substrate isocitrate. In the presence of ADP and calcium, the concentration of isocitrate needed for the enzyme to work at half-speed drops from 227 micromolar to just 53 micromolar. This calcium sensitivity has been observed in mitochondria from heart, liver, kidney, and fat tissue, suggesting it’s a universal regulatory mechanism. The interplay matters: inhibition by ATP and NADH is strongest when these activators are absent.
Substrate Inhibition at High Concentrations
Isocitrate dehydrogenase also appears on the list of enzymes subject to substrate inhibition, meaning that very high concentrations of isocitrate itself can paradoxically slow the reaction. This is a recognized kinetic phenomenon across many enzymes and likely serves as a built-in safety valve, preventing the enzyme from running too fast when substrate floods the system. Under normal physiological conditions, substrate levels rarely reach inhibitory concentrations, so this form of inhibition mainly matters in experimental or extreme metabolic scenarios.
Aluminum and Oxidative Stress
Aluminum is a well-documented inhibitor of the NADP+-dependent isoforms (IDH1 and IDH2). It acts as a partial competitive inhibitor with respect to isocitrate and a noncompetitive inhibitor with respect to NADP+, with an inhibition constant of just 0.88 micromolar, meaning very small amounts can have a measurable effect. The inhibition is also pH-dependent, becoming more pronounced under slightly acidic conditions.
The consequences of aluminum’s inhibition extend beyond simply slowing the enzyme. IDH2 is the primary source of NADPH inside mitochondria, and NADPH is essential for regenerating glutathione, the cell’s main antioxidant defense molecule. When aluminum blocks IDH2, NADPH production drops, glutathione can’t be recycled from its oxidized form back to its active reduced form, and the cell becomes more vulnerable to oxidative damage. In the cytoplasm, aluminum also inhibits IDH1 and malic enzyme, both of which supply NADPH, compounding the problem.
Beyond aluminum, several reactive oxygen species directly inactivate IDH2. These include 4-hydroxynonenal (a byproduct of fat oxidation), hypochlorous acid (produced by immune cells), nitric oxide, and peroxynitrite. This creates a vicious cycle: oxidative stress damages IDH2, which reduces the cell’s ability to make the antioxidant glutathione, which leaves the cell even more susceptible to oxidative stress.
Pharmaceutical Inhibitors for Cancer
Mutations in IDH1 and IDH2 give these enzymes a new, harmful function. Instead of converting isocitrate to alpha-ketoglutarate, the mutant enzymes run a different reaction that produces a compound called D-2-hydroxyglutarate (D-2-HG). Normal cells keep D-2-HG below 0.1 millimolar, but cells with IDH mutations produce more than 100-fold that amount. At concentrations of 2 to 5 millimolar, D-2-HG interferes with gene regulation and drives tumor growth in cancers like acute myeloid leukemia and brain gliomas.
This discovery led to a new class of drugs designed not to inhibit normal IDH, but to specifically block the mutant enzyme’s ability to produce D-2-HG. The first synthetic inhibitor, called AGI-5198, was shown to block D-2-HG production in cells carrying IDH mutations and reverse some of the cancer-promoting effects. From there, several drugs advanced through clinical development:
- Ivosidenib (AG-120): A selective inhibitor of mutant IDH1, approved for acute myeloid leukemia.
- Enasidenib: A selective inhibitor of mutant IDH2, also approved for acute myeloid leukemia.
- Vorasidenib (AG-881): A dual inhibitor of both mutant IDH1 and IDH2, designed to cross the blood-brain barrier. In August 2024, the FDA approved vorasidenib for patients 12 and older with Grade 2 astrocytoma or oligodendroglioma carrying a susceptible IDH1 or IDH2 mutation. This was the first systemic therapy ever approved for these slow-growing brain tumors. In the phase 3 INDIGO trial, patients took 40 mg orally once daily in 28-day cycles until their disease progressed or side effects became unacceptable.
These drugs are highly specific to the mutant forms of IDH and do not significantly affect the normal, wild-type enzymes or IDH3. No targeted pharmaceutical inhibitors of wild-type IDH1, IDH2, or IDH3 are in clinical use, because inhibiting normal IDH activity would disrupt healthy cellular metabolism.
How IDH3 Differs From IDH1 and IDH2
The three isoforms share a name and catalyze similar reactions, but they differ in structure, location, and regulation. IDH1 sits in the cytoplasm, IDH2 in the mitochondrial matrix, and both use NADP+ to produce NADPH. Their reactions are reversible. IDH3, the citric acid cycle enzyme, uses NAD+ instead, producing NADH, and its reaction runs in only one direction under normal conditions. Structurally, IDH3 is far more complex: it assembles as a pair of four-subunit complexes, while IDH1 and IDH2 function as simple two-subunit pairs.
These differences matter for inhibition. IDH3 is the isoform regulated by ATP, NADH, and calcium as part of moment-to-moment energy balancing. IDH1 and IDH2 are more susceptible to damage from aluminum and reactive oxygen species, with direct consequences for the cell’s antioxidant capacity. And only the mutant forms of IDH1 and IDH2, not IDH3, have been linked to cancer and targeted by drugs.